Status:

COMPLETED

Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

Maquet Cardiopulmonary GmbH

Conditions:

Acute Respiratory Distress Syndrome (ARDS)

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This international multicenter, randomized, open trial will evaluate the impact of Extracorporeal Membrane Oxygenation (ECMO), instituted early after the diagnosis of acute respiratory distress syndro...

Detailed Description

Background: The acute respiratory distress syndrome (ARDS) is generally a severe pulmonary disease, whose associated mortality remains high. The most severe forms of ARDS, during which the hypoxemia i...

Eligibility Criteria

Inclusion

  • Inclusion criteria :
  • ARDS defined according to the following criteria (9) :
  • Intubation and mechanical ventilation for ≤ 6 days
  • Bilateral radiological pulmonary infiltrates consistent with edema
  • PaO2/FiO2 ratio \< 200 mm Hg
  • Absence of clinical evidence of elevated left atrial pressure and/or pulmonary arterial occlusion pressure ≤ 18 mm Hg
  • One of the 3 following criteria of disease severity:
  • i. PaO2/FiO2 \< 50 mm Hg with FiO2 ≥ 80% for \> 3 hours, despite optimization of mechanical ventilation (Vt set at 6 ml/kg and trial of PEEP ≥ 10 cm H2O) and despite possible recourse to usual adjunctive therapies (NO, recruitment maneuvers, prone position, HFO ventilation, almitrine infusion) OR
  • ii. PaO2/FiO2 \< 80 mm Hg with FiO2 ≥ 80% for \> 6 hours, despite optimization of mechanical ventilation (Vt set at 6 ml/kg and trial of PEEP ≥ 10 cm H2O) and despite possible recourse to usual adjunctive therapies (NO, recruitment maneuvers, prone position, HFO ventilation, almitrine infusion) OR
  • iii. pH \< 7.25 (with PaCO2 ≥60 mm Hg) for \> 6 hours (with respiratory rate increased to 35/min) resulting from MV settings adjusted to keep plat ≤ 32 cm H2O (first, tidal volume reduction by steps of 1 mL/kg to 4 mL/kg then PEEP reduction to a minimum of 8 cm H2O.
  • Obtain informed consent from a close relative or surrogate. Should such a person be absent, the patient will be randomized according to the specifications of emergency consent and the patient will be asked to give his/her consent for the continuation of the trial when his/her condition will allow.
  • Exclusion criteria :
  • Intubation and mechanical ventilation for ≥ 7 days
  • Age \< 18 years
  • Pregnancy
  • Weight \> 1 kg/cm or BMI \> 45 kg/m²
  • Chronic respiratory insufficiency treated with oxygen therapy of long duration and/or long-term respiratory assistance
  • Cardiac failure requiring veno-arterial ECMO
  • Previous history of heparin-induced thrombopenia
  • Oncohaematological disease with fatal prognosis within 5 years
  • Patient moribund on the day of randomization or has a SAPS II \> 90
  • Non drug-induced coma following cardiac arrest
  • Irreversible neurological pathology, for example, flat EEG tracing cerebral herniation…
  • Decision to limit therapeutic interventions
  • ECMO cannula access to femoral vein or jugular vein impossible.
  • CardioHelp device not immediately available

Exclusion

    Key Trial Info

    Start Date :

    December 8 2011

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 1 2017

    Estimated Enrollment :

    249 Patients enrolled

    Trial Details

    Trial ID

    NCT01470703

    Start Date

    December 8 2011

    End Date

    September 1 2017

    Last Update

    December 21 2018

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Groupe Hospitalier Pitié Salpêtrière

    Paris, France, 75013